Cochrane · systematic review · CD012502
Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
Zhan, S, Tang, M, Liu, F, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
HeartAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
7
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 14.3%Low 1 · 14.3%Moderate 4 · 57.1%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events
Population: people with cardiovascular disease or at high risk of cardiovascular disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Major adverse cardiovascular events (MACE) | RR 0.94 [0.9, 0.98] | 10 studies · 21727 participants | Moderate Downgraded: risk of bias |
All‐cause mortality | RR 0.98 [0.91, 1.05] | 8 studies · 21222 participants | High |
Myocardial infarction (non‐fatal) | RR 0.88 [0.81, 0.95] | 6 studies · 21145 participants | Moderate Downgraded: risk of bias |
Stroke (non‐fatal) | RR 0.83 [0.71, 0.97] | 6 studies · 21205 participants | Moderate Downgraded: risk of bias |
Cardiovascular mortality | RR 1 [0.89, 1.12] | 6 studies · 19457 participants | Moderate Downgraded: risk of bias, imprecision |
Adverse events ‐ hepatopathy | RR 1.14 [0.96, 1.35] | 4 studies · 20687 participants | Low Downgraded: risk of bias |
Adverse events ‐ myopathy | RR 1.31 [0.72, 2.38] | 3 studies · 20581 participants | Very low Downgraded: risk of bias |